2016

29/12/2016

Change of Director’s Interest Notice

29/12/2016

Change in Substantial Holding

28/12/2016

Proteomics Completes Heavily Oversubscribed Share Purchase Plan

28/12/2016

Change in Substantial Holding

28/12/2016

Change in Substantial Holding

28/12/2016

Appendix 3B

19/12/2016

Diabetic Kidney Disease Patent Granted in Russia

13/12/2016

Appendix 3B

13/12/2016

Secondary Trading Notice

07/12/2016

Share Purchase Plan Offer Document

06/12/2016

Notice Pursuant to ASIC Class Order 09/425

02/12/2016

Proteomics Completes $1.44 million Placement and Offers SPP

30/11/2016

Trading Halt

17/11/2016

Outcome of AGM

17/11/2016

Proteomics AGM Presentation

15/11/2016

Proteomics and Linear to offer end-to-end testing and clinical trials

11/11/2016

PromarkerD Test Kit Production Deal Signed

31/10/2016

Proteomics Wins WA Exporter of the Year

26/10/2016

Proteomics Presents at Australia Biotech Invest 2016

25/10/2016

Quarterly Report – Appendix 4C

20/10/2016

Proteomics Targets Gastro-causing Parasite

19/10/2016

Notice of Annual General Meeting/Proxy Form

14/10/2016

Proteomics Appoints New Director

04/10/2016

Research Report

21/09/2016

Proteomics International Receives FY16 R&D Tax Incentive

06/09/2016

Proteomics Investigates Biomarkers for Mesothelioma

26/08/2016

Corporate Governance Statement and Appendix 4G

26/08/2016

Annual Report to Shareholders

26/08/2016

Preliminary Final Report

24/08/2016

Proteomics International Expands Diagnostics Portfolio to Endometriosis

28/07/2016

Quarterly Business Update

29/06/2016

PIQ Board Changes

14/06/2016

PromarkerD Development Advances in China

20/05/2016

Proteomics Gaining Strong Traction in Analytical Services

15/04/2016

Proteomics to Expand Operations in Indian Market

23/03/2016

Proteomics Commences Therapeutic Drug Discovery Program

07/03/2016

PromarkerD Update

16/02/2016

Appendix 3B

09/02/2016

New Company Website and Corporate Video

21/01/2016

Proteomics International Quarterly Business Update

Subscribe
  • This field is for validation purposes and should be left unchanged.